Overexpressed human thymidine phosphorylase (hTP) has been associated with cancer
aggressiveness and poor prognosis by triggering proangiogenic and
antiapoptotic signaling. Designed as transition-state analogues by
mimicking the oxacarbenium ion, novel pyrimidine-2,4-diones were synthesized
and evaluated as inhibitors of hTP activity. The most potent compound
(8g) inhibited hTP in the submicromolar range with a
noncompetitive inhibition mode with both thymidine and inorganic phosphate
substrates. Furthermore, compound 8g was devoid of apparent
toxicity to a panel of mammalian cells, showed no genotoxicity signals,
and had low probability of drug–drug interactions and moderate
in vitro metabolic rates. Finally, treatment with 8g (50
mg/(kg day)) for 2 weeks (5 days/week) significantly reduced tumor
growth using an in vivo glioblastoma model. To the best of our knowledge,
this active compound is the most potent in vitro hTP inhibitor with
a kinetic profile that cannot be reversed by the accumulation of any
enzyme substrates.
Using cycloalkyl and electron-donating groups to decrease
the carbonyl
electrophilicity, a novel series of 2-(quinoline-4-yloxy)acetamides
was synthesized and evaluated as in vitro inhibitors
of Mycobacterium tuberculosis (Mtb) growth. Structure–activity
relationship studies led to selective and potent antitubercular agents
with minimum inhibitory concentrations in the submicromolar range
against drug-sensitive and drug-resistant Mtb strains. An evaluation
of the activity of the lead compounds against a spontaneous qcrB mutant strain indicated that the structures targeted
the cytochrome bc
1 complex. In addition,
selected molecules inhibited Mtb growth in a macrophage model of tuberculosis
infection. Furthermore, the leading compound was chemically stable
depending on the context and showed good kinetic solubility, high
permeability, and a low rate of in vitro metabolism.
Finally, the pharmacokinetic profile of the compound was assessed
after oral administration to mice. To the best of our knowledge, for
the first time, a 2-(quinoline-4-yloxy)acetamide was obtained with
a sufficient exposure, which may enable in vivo effectiveness
and its further development as an antituberculosis drug candidate.
The emergence of strains of Mycobacterium tuberculosis resistant to isoniazid (INH) has underscored the need for the development of new anti-tuberculosis agents. INH is activated by the mycobacterial katG-encoded catalase-peroxidase, forming an acylpyridine fragment that is covalently attached to the C4 of NADH. This isonicotinyl-NAD adduct inhibits the activity of 2-trans-enoyl-ACP(CoA) reductase (InhA), which plays a role in mycolic acid biosynthesis. A metal-based INH analog, Na3[FeII(CN)5(INH)]·4H2O, IQG-607, was designed to have an electronic redistribution on INH moiety that would lead to an intramolecular electron transfer to bypass KatG activation. HPLC and EPR studies showed that the INH moiety can be oxidized by superoxide or peroxide yielding similar metabolites and isonicotinoyl radical only when associated to IQG-607, thereby supporting redox-mediated drug activation as a possible mechanism of action. However, IQG-607 was shown to inhibit the in vitro activity of both wild-type and INH-resistant mutant InhA enzymes in the absence of KatG activation. IQG-607 given by the oral route to M. tuberculosis-infected mice reduced lung lesions. Experiments using early and late controls of infection revealed a bactericidal activity for IQG-607. HPLC and voltammetric methods were developed to quantify IQG-607. Pharmacokinetic studies showed short half-life, high clearance, moderate volume of distribution, and low oral bioavailability, which was not altered by feeding. Safety and toxic effects of IQG-607 after acute and 90-day repeated oral administrations in both rats and minipigs showed occurrence of mild to moderate toxic events. Eight multidrug-resistant strains (MDR-TB) were resistant to IQG-607, suggesting an association between katG mutation and increasing MIC values. Whole genome sequencing of three spontaneous IQG-607-resistant strains harbored katG gene mutations. MIC measurements and macrophage infection experiments with a laboratorial strain showed that katG mutation is sufficient to confer resistance to IQG-607 and that the macrophage intracellular environment cannot trigger the self-activation mechanism. Reduced activity of IQG-607 against an M. tuberculosis strain overexpressing S94A InhA mutant protein suggested both the need for KatG activation and InhA as its target. Further efforts are suggested to be pursued toward attempting to translate IQG-607 into a chemotherapeutic agent to treat tuberculosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.